Inositol derivatives for use in pathological crystallization

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent relates to a specific group of chemical compounds—inositol polyphosphate oligo alkyl ether compounds or their pharmaceutically acceptable salts—that are intended to treat or prevent diseases linked to the formation of calcium salt crystals in the body.

Use CasesContent extracted from patent full text and abstract with AI.

• Treating kidney stones caused by calcium salt crystallization
• Preventing recurrence of kidney stones in patients prone to such conditions
• Managing diseases like calcification of blood vessels or tissues
• Potentially treating other pathological conditions involving calcium salt deposits, such as certain forms of arthritis

BenefitsContent extracted from patent full text and abstract with AI.

• May offer a new oral or injectable pharmaceutical option for patients with crystallization-related diseases
• Could reduce recurrence rates of diseases like kidney stones
• Has the potential to decrease the need for invasive treatments like surgery
• Improves patient outcomes by addressing the underlying pathological crystallization
• Expands the choice of therapeutic compounds for clinicians treating these conditions

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention is related to an inositol polyphosphate oligo alkyl ether compound, or its pharmaceutically acceptable salt, for use in treatment or prevention of a disease associated with formation of calcium salt crystals.